Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement with Washington University in St. Louis, one of the world’s leading research institutions, for the development of Wugen’s Memory Natural Killer (NK) Cell program.
